Pluvicto life expectancy: an honest look at the numbers.

What the VISION trial actually showed

The VISION trial enrolled 831 men with metastatic castration-resistant prostate cancer who had progressed on at least one androgen-receptor-pathway inhibitor (such as abiraterone or enzalutamide) and at least one taxane-based chemotherapy regimen. All patients had a positive Ga-68 PSMA PET-CT showing adequate PSMA expression. The trial randomised patients to receive either Pluvicto plus best standard of care, or best standard of care alone.

The median overall survival was 15.3 months in the Pluvicto arm compared with 11.3 months in the standard-of-care-alone arm — a benefit of approximately 4 months at the median. The median radiographic progression-free survival was 8.7 months on Pluvicto compared with 3.4 months on standard of care alone. The PSA-50 response rate (a decline in PSA of 50 percent or more) was 46 percent on Pluvicto compared with 7 percent on the control arm.

How to read a median survival number

The most important thing to understand about median overall survival is that it is the time at which 50 percent of patients are still alive. Half the patients reach this point and continue beyond it; half do not. Some patients live a few months; some live well beyond 30 months. The median is a useful summary statistic, but it does not predict any individual patient's outcome.

The factors that move an individual patient toward the longer end of the distribution include: PSMA-positive disease with high uptake intensity on the staging PET-CT, lower baseline disease burden, no visceral metastases, fewer prior lines of therapy, preserved performance status, normal baseline alkaline phosphatase, and normal baseline lactate dehydrogenase. The factors that move toward the shorter end include the opposite of these — high baseline disease burden, visceral metastases, poor performance status, elevated alkaline phosphatase and LDH, and prior progression through multiple therapy lines.

Real-world outcomes since approval

Real-world data since 2022 — when Pluvicto became available outside trial settings — has broadly confirmed the VISION outcomes in similar patient populations. Some real-world series have reported slightly better PSA response rates, possibly reflecting more careful patient selection in routine practice (where PSMA PET-CT eligibility cutoffs may be applied more strictly than the trial protocol).

Importantly, real-world data has also clarified outcomes in patient subgroups that were less well represented in VISION, including patients with high tumour burden, patients with visceral metastases, and patients receiving Pluvicto earlier in their disease course (before extensive taxane chemotherapy). Several trials — including PSMAfore, which evaluated Pluvicto before taxane chemotherapy — are now expanding the formal evidence base into earlier disease settings.

What happens when Pluvicto stops working

For most patients, Pluvicto eventually stops controlling the disease. When this happens, several options exist. Some patients with persistent PSMA expression on follow-up imaging are candidates for Ac-225 PSMA therapy (an alpha-emitter version of the same therapy), available under the Helsinki Declaration framework with written informed consent. Other patients may benefit from re-challenge with Pluvicto after a treatment-free interval, particularly if the disease remains PSMA-positive. Still others may move to a different therapy class entirely — cabazitaxel chemotherapy, Ra-223 for bone-predominant disease, PARP inhibitors for patients with specific genetic mutations, or supportive care depending on the clinical context.

The honest framing is that Pluvicto is part of a sequence of therapies in advanced prostate cancer, not a standalone cure. The sequence is what produces meaningful life expectancy gains; each individual therapy adds months. Together, the modern toolkit has substantially extended life expectancy in mCRPC compared with what was possible ten years ago.

How to interpret these numbers for yourself

The numbers above describe the average experience in a defined trial population. For an individual patient, the meaningful questions are: what does my PSMA PET-CT show, how heavy is my disease burden, what is my performance status, what are my baseline blood tests, and how many prior therapies have I had. With these factors mapped, a more individualised expectation is possible — though it remains an expectation, not a prediction.

The other meaningful question is what matters to the patient personally. A 4-month median benefit in overall survival is statistically significant; for some patients, those months represent specific personal milestones — a wedding, a grandchild's birth, a long-planned trip — that make the treatment intensely worthwhile. For others, the priority is quality of life over duration, and the side-effect profile of Pluvicto is part of the decision. There is no single right answer; the conversation with your nuclear medicine and medical oncology team is what produces the right answer for you.

Where to go from here

If you are considering Pluvicto, the most useful preparation is a recent Ga-68 or F-18 PSMA PET-CT (ideally within the last six weeks), recent kidney function and full blood count results, recent PSA, your complete treatment history, and a written list of every medication you are taking. With that on the table, an honest assessment of expected benefit is straightforward. At FMRI Gurugram we run a dedicated nuclear oncology clinic for advanced prostate cancer, with full Lu-PSMA delivery capability and access to Ac-225 PSMA salvage therapy where indicated. The first step is a consultation in which we walk you through the realistic picture for your specific situation.